Monday, September 15, 2025 9/15/2025

Deiminated molecules as markers for developing pancreatic cancer - A1

Award Number: R21CA279916
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 12/15/2023
PERIOD OF PERFORMANCE END DATE: 11/30/2025

Group Awards By:

View Award Description

Deiminated molecules as markers for developing pancreatic cancer - A1 - PROJECT SUMMARY/ABSTRACT Pancreatic ductal adenocarcinoma (PDA) carries a dismal prognosis. Understanding the mechanisms that lead to the development of pancreatic cancer and to identify markers that distinguish between non-cancerous and cancerous lesions is the greatest hope for early detection and early treatment of patients. This proposal focusses on identifying early detection markers that would allow resection of tumors at a time point where they are still local. It is our hypothesis that pancreatic high-grade lesions significantly distinguish from low- grade lesions by expressing PADI1. We further hypothesize that PADI1 and its citrullinated substrates can be detected in pancreatic biopsy and may form a panel of markers specific for early detection of PDA. To test this we will: verify PADI1 as a specific marker for HG lesions and test its presence in liquid biopsies (Specific Aim 1); characterize citrullinated fibrinogen as a PADI1 substrate and marker for pancreatic cancer (Specific Aim 2); and identify pancreas cancer specific PADI1-citrullinated substrates (intracellular and secreted) in lesions and in liquid biopsy (Specific Aim 3). Successful completion of our project will identify secreted protein markers that are detectable in easily accessible liquid biopsy (blood serum) and distinguish between pancreatic non-cancerous lesions and PanIN3 (carcinoma in situ) and PDA lesions.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $219,491 )
2025	2025	MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION)	4500 SAN PABLO RD S	JACKSONVILLE	FL	32224	DUVAL	USA	Cancer Detection and Diagnosis Research	000	2	11/15/2024	NON-COMPETING CONTINUATION	$197,542
2025	2025	MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION)	4500 SAN PABLO RD S	JACKSONVILLE	FL	32224	DUVAL	USA	Cancer Detection and Diagnosis Research	001	2	6/2/2025	NON-COMPETING CONTINUATION	$21,949
														Subtotal = $219,491

Issue Date FY: 2024 ( Subtotal = $182,909 )
2024	2024	MAYO CLINIC JACKSONVILLE (A NONPROFIT CORPORATION)	4500 SAN PABLO RD S	JACKSONVILLE	FL	32224	DUVAL	USA	Cancer Detection and Diagnosis Research	000	1	12/15/2023	NEW	$182,909
														Subtotal = $182,909

Grand Total All Awards = $402,400

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Deiminated molecules as markers for developing pancreatic cancer - A1

Award Number: R21CA279916

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 12/15/2023

PERIOD OF PERFORMANCE END DATE: 11/30/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer